Introduction
Von Willebrand factor (VWF) circulates in plasma as multimers after release from endothelial cells or activated platelets. VWF circulates in a globular form, but it has an unfolded conformation during its release. 1 In this state, VWF can directly bind platelets via its A1 domain 2 and passively bridge multiple platelets together without inducing their activation (agglutination).
The metalloprotease ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type I motif, member 13) cleaves VWF in its A2 domain 3 , preferably when VWF is unfolded. 4 This proteolysis is essential to prevent the formation of ultralarge VWF multimers and pathological platelet-VWF complexes that obstruct the microvasculature, as occurs in patients with thrombotic thrombocytopenic purpura (TTP). 5 TTP patients characteristically experience recurrent episodes of microangiopathy, intermitted by prolonged remission periods. This is thought to be a result of fluctuating ADAMTS13 activity levels, triggered by inhibitory antibodies. Remarkably, patients and mice that are completely and persistently deficient in ADAMTS13 activity, can achieve remission and do not present with continuous symptoms of microangiopathy. 6 This suggests that additional factors beyond ADAMTS13 activity modulate the presentation of TTP attacks.
We here propose a hypothesis that may help to explain the unpredictable nature of TTP pathology: a second proteolytic mechanism exists that is capable of degrading dangerously large VWF-platelet complexes in absence of ADAMTS13. One candidate enzyme that can substitute for ADAMTS13 and degrade platelet-VWF complexes is plasmin. Active plasmin is able to cleave VWF and alters its platelet-binding capacity under purified conditions. 7, 8 Plasminogen can be activated by tissue-type plasminogen activator (tPA) or urokinase-type plasminogen activator (uPA) . Whereas tPA has a high affinity for fibrin, 9 uPA has little affinity for fibrin prior to with thrombotic thrombocytopenic purpura (TTP). 5 TTP patients characteristical ally l ly e e exp xp per r erie ie ienc nc nce e ecurrent episodes of microangiopathy, intermitted by prolonged remission periods. This is h hou ou ugh gh ght t t to to to b b be a re re es su sult of fluctuating ADAMTS13 3 3 ac c ctivity levels, tr tr rigge ge ere re red d by inhibitory an nti i ib bodies. Re ema ma ar rk kab ab bly ly, , pa pa pati ti ien en nts ts a a an nd nd m m mi ice t th ha a at ar re e c comp mp mple let te t l ly ly a and nd d p per ersi s s s sten en ntl tl tly y de de efi fi ici ci cien en nt in in in AD AD DAM AM AMTS TS13 13 13 a act ct tiv iv vit ity, y, , ca an an ach ch chie ie eve ve ve r r rem em mis is ssi si sion on on a a and nd n d do o o no no ot t pr pr pre e esen en ent t wi wi with th th c con on onti tinu nu uou ou us s sy sy symp mp mpto toms ms m o of f f microangiopa pa path th thy. y. y 6 6 6 T T Thi hi is s su ugg gg gges e e ts ts ts t t tha ha at t a a add dd ddit it itio io iona na n l l l fa fa f ct ct ctor or o s s be be beyo yo yond nd d AD AD ADAM AM AMTS TS TS13 13 1 a a act ct ctiv iv ivit it ity y y modulate activation. 10 As a result, tPA is considered the most important plasminogen activator in fibrinolysis. 11 In contrast, uPA becomes an efficient plasminogen activator on its receptor uPAR, which is amongst others presented by activated endothelial cells during hypoxia. 12, 13 In this study, we investigated whether plasmin could substitute for ADAMTS13 to degrade platelet-VWF complexes. We found evidence that plasmin can destruct platelet agglutinates and is triggered during microangiopathy. Furthermore, we found that induction of plasminogen activation by thrombolytic agents can be used to controllably degrade platelet agglutinates in vitro and in vivo, which may offer therapeutic opportunities for the complicated clinical management of TTP.
Materials and Methods
Methods of blood collection, HUVEC isolation and culture, immunofluorescence microscopy, determination of VWF release by enzyme-linked immunosorbent assay (ELISA), biochemical interaction studies, platelet aggregation and -agglutination studies, western blotting and substrate conversion assays are provided in the online-only data supplement.
Real-time microscopy of platelet-VWF complex formation on HUVEC
Confluent HUVEC were cultured on glass coverslips and pre-activated with 100 nM phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, Zwijndrecht, the Netherlands) for 60 minutes.
Coverslips were placed into a laminar-flow perfusion chamber under an inverted microscope (Zeiss observer Z.1, Carl Zeiss, Sliedrecht, the Netherlands). Lyophilized platelets (BioData Corporation, Horsham, USA) were resuspended in serum-free M199 culture medium (Invitrogen) and perfused at a shear rate of 300 sec -1 , triggering platelet-VWF string formation.
String stability was ensured during 5 minutes of perfusion. Next, serum-free M199 medium
Materials and Methods
Me Meth th thod od ods s of of of b b blo l od od d c col o lection, HUVEC isolation a a and nd nd culture, immu mu unofl fl luo uo uore r scence microscopy, d de dete e erm r ination n of of of V V VWF WF WF r r rel el ele ea ease se se b by y en en nzy zy ym m me-li i ink k ked im m mmu mu un no nos so or rb rben en nt as assa say y y ( (E (ELI LI LIS SA SA), ), b b bio io ioch ch c em em emic c ical al l n nte te tera ra act ct c io ion n st st stud udie ie es, s, , p pla la ate e ele let t ag ag ggr gr reg eg egat at atio ion n n an an and d d -a a agg gg ggl l lut ut tin inat at a io io ion n n st stud ud udi ie es, s, w w we es este e er rn n bl bl blot ot o ti ting ng ng an n nd s sub ub bst str ra rate conversion a ass ss say ay ays s s ar ar are e pr pr prov v vid id ided ed e i i in n n th th he e on on onli li line ne ne-o -o onl nl n y y y da da data ta s s sup up uppl pl plem em men en e t. . . containing 100 mM PMA, with 216 g/mL plasminogen, 10 ng/mL uPA, 10 U/mL streptokinase, 2 g/mL anti-uPAR (R&D systems, Abingdon, UK; Clone 62022) or 200 mM ACA or in combinations was perfused over platelet-VWF strings. Similarly, perfusions were performed in the presence of 5 g/mL ADAMTS13 (R&D systems), 20 nM elastase (from human leukocytes, Sigma-Aldrich) and 300 nM granzyme B and M (generously provided by Dr.
Niels Bovenschen).
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MM-L-Tyr-Arg-pNA, Roche) and conversion was measured at 405nm for 300 seconds. Slopes were determined and related to the capacity of NPP (defined as 100%) to inhibit plasmin activity.
In vivo studies
Animal studies were performed in accordance with protocols approved by the Institutional 16 ) was intravenously administered via the left retro-orbital plexus (5 minutes n=5; 15 minutes n=10). As controls, completely untreated mice (n=8) and mice that were treated with thrombolytic treatment without being challenged with rhVWF (n=5) were taken along. After 24 hours, venous blood was drawn into trisodium citrate (resulting in a final concentration of 0.61% w/v) and the mice were exsanguinated under deep anesthesia by isoflurane. Cell counts were determined within 30 minutes using a Hemavet
Hematology system (Drew Scientific, Dallas, USA). Heart, kidneys and liver were collected from all mice, rinsed in PBS and fixed in 4% paraformaldehyde overnight and embedded in paraffin. Four m sections were cut and stained with Haematoxylin-Eosin for morphological analysis. Pictures were taken using an Olympus DP71 camera with a 40x objective and Cell^P imaging software (Olympus, Zoeterwoude, the Netherlands).
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Statistics
Statistical comparisons between two groups of samples were performed by Mann-Whitney U testing and indicated by horizontal lines with T-ends (displayed in the graphs as |---| ).
Comparisons between multiple groups were performed by Kruskal-Wallis testing, indicated by a
horizontal line with open ends (displayed in the graphs as ---). A p-value of less than 0.05 was considered significant. All data analyses were performed with computer software (IBM SPSS Statistics 20.0, SPSS Inc., Chicago, IL, USA).
Results

Plasmin degrades platelet-VWF complexes on endothelial cells
To investigate whether plasmin formation on endothelial cells could substitute for ADAMTS13, Figure 2A) and support uPA-dependent plasmin activity after stimulation (Supplemental Figure 2B) . It was previously reported that platelet-VWF complexes are efficiently degraded by ADAMTS13. 4 We next investigated whether the binding of platelets was required for the cleavage of VWF by plasmin. In line with our earlier findings, activated HUVEC retain part of their released VWF on their surface after activation (i.e. not all is released into the supernatant as soluble VWF). Next, we exposed these cells (after replacing the supernatant medium) to plasminogen only, or uPA and plasminogen together. In the presence of uPA and plasminogen together, the vast majority of VWF was removed from the cell surface within one hour ( Figure 1E ) and was now present in the supernatant ( Figure 1D ). In Plasminogen binds to and cleaves VWF in a lysine-dependent manner.
ADAMTS13 requires direct binding to VWF for cleavage. 17 In similar fashion, we found that plasminogen can bind directly to immobilized VWF (Figure 2A ). This binding is completely Figure 1D ). Moreover, platelet-VWF co omp mp mple le lexe xes s s on on on end nd ndo ot othelial cells were not degraded ed ed b b by plasminoge en n n in t t the he he presence of tPA under fl fl low w w (not show wn) n) n . Th h he e ese e e re re esu su ult lt ts s to to oge ge geth th her r r ind d dic c cate th h hat uP uP uPA-A--de de epe pend nd den nt t pl p p as asm mi min n n fo form rm rmat at a io io ion n n ca can n n n nde de depe pe pend nd n en en ntl tl tly y de de egr gr rad ade e V VW VWF F F on on n e e en n ndo d doth th hel el elia ia ial l l ce e ell ll l s s in n n th he he p p pre re rese se enc nc n e e e an an and d d a ab abs se senc nc ce e of of o p p pla la at tel le ets s s, , although wit th h h di di diff ff fer er erin in ing g g ef e fi fi fica ca cacy cy y. . Figure 2E ). Together, these findings suggest that lysine-dependent interactions between VWF and plasmin are required for the cleavage of VWF.
Supplemental Movie 5; quantification in
ADAMTS13 recognizes VWF in its globular conformation, but requires unfolding in order to cleave the A2 domain. 17 As 
Streptokinase-activated plasminogen degrades platelet-VWF complexes
We next investigated whether therapeutic thrombolytic agents that trigger plasminogen activation can be applied to degrade platelet-VWF complexes and bypass the necessity for uPA Figure 3B ). This suggests that binding of plasminogen to VWF is mediated by a a bi bind nd ndin in ng g g si si site te te t tha s cryptic in globular VWF. We next aimed to identify a plasminogen binding site in VWF. VWF co ont nt ntai ai ain ns ns n n num um umerou ou us s s ly l sine residues throughout the he he m m molecule h h htt tp p: p //www.un unip ip ipro ot. t or org/ g/ /un un nip ip pro ro rot/ t/P P P04 04 42 27 75 5). T Th he e e mo o os st t lys ys ysi in ine-e-ri ich ch a a are e ea a in in n th he he m m ma at atur ure e e m mo mole le l cu cu cul le le e esi si side de des s s in in V V VWF WF W A A A1 1 1 do do om ma main in: KK KK KKKK KK KK 138 138 83--1 1386 386 . . We We We t t the he here r fo fo f re re re i i inv nv ves es e t ti tiga ga ate te ted d d w wh whet et the he her r r th th his is is do om omai ain n is is has the capaci ci ity ty ty t to o o bi bi b nd nd nd p pla a asm sm smin n nog og ogen en en ind nd ndep ep epen en ende de den n ntl tl ly. y. y. F Fir ir rst st s , , we we we c c con on o fi fi firm rm rmed ed ed t t tha ha h t t pl pl plas as asmi mi mino n n gen or ADAMTS13. Hereto, we activated plasminogen with streptokinase, which is used in the treatment of myocardial infarction and pulmonary embolism. Streptokinase-activated plasminogen gradually degraded purified VWF in solution (Supplemental Figure 3C) , as was reported earlier for purified plasmin. 7 Furthermore, streptokinase-activated plasminogen rapidly Figure 4E ). We next investigated whether plasmin-mediated destruction of platelet-VWF complexes was restricted to the surface of endothelial cells, which are known to express lysine-dependent receptors for plasminogen. 19 Hereto, we triggered platelet agglutination by ristocetin in the presence of streptokinase-activated plasminogen. Although platelet-VWF complexes formed normally in the presence of plasmin activity, they became unstable and fell apart immediately after full agglutination ( Figure 3D ). In contrast, the addition of plasminogen alone, or in the presence of uPA or tPA did not induce degradation of these complexes (indicating a critical role for uPAR). Moreover, platelet agglutinates in suspension were protected against degradation by streptokinase-activated plasminogen in the presence of ACA ( Figure 3E ) and addition of ACA after the onset of plasmin digestion immediately halted further degradation ( Figure 3E ; ACA added after 9 minutes of agglutination is indicated by black arrow). In similar experiments, we found that ADAMTS13, neutrophil elastase, granzyme M and -B were unable to directly (i.e. normally in th th he e e pr pr pres es esen en ence ce e o of f f pl pl plas s smi mi m n n n ac ac cti ti tivi vi vity ty y, , th th they ey ey b b bec ec e am m me e e un un unst st stab ab able e a a and nd nd f f fel el ell l l ap ap par ar art t t im im imme m m diately (Supplemental Figure 4F) . Also in platelet-rich plasma, ristocetin-induced platelet agglutinates were sensitive to breakdown by streptokinase-activated plasminogen in a lysine-dependent manner ( Figure 3F ). These data indicate that thrombolytic plasminogen activators can bypass ADAMTS13 and uPA to induce the breakdown of platelet agglutinates.
Uncontrolled plasmin activity can affect multiple important targets in the hemostatic system, which are involved in platelet aggregation and hemostasis (e.g. fibrinogen or platelet Glycoprotein Ib 20 ). We therefore investigated whether the levels of streptokinase-activated plasminogen that degrade platelet-VWF complexes, also generally affect platelet aggregate formation. Hereto, we triggered platelet activation by type I collagen or -thrombin. Both these physiological agonists induced complete and irreversible platelet aggregation in the presence of streptokinase-activated plasminogen ( Figure 4A,B) . However, we found that the initial phase of platelet aggregation was delayed, suggesting an auxiliary role for VWF during the initiation of aggregate formation. Under flow, platelet aggregate formation on immobilized collagen at arterial shear remained unaffected in the presence of streptokinase-activated plasminogen ( Figure 4C ; quantification of surface coverage in Figure 4D ), even when whole blood was preincubated with a high dose of streptokinase (100 U/mL) for 5 minutes prior to perfusion (Supplemental Movies 8 (control) and 9 (streptokinase)). Together, these data indicate that neither globular plasma VWF, nor collagen-bound VWF form efficient targets for plasminmediated breakdown, whereas platelet-VWF complexes are rapidly degraded.
Plasminogen activation during thrombotic thrombocytopenic purpura attacks
Given the effects of plasmin on platelet-VWF complexes, we hypothesized that plasminogen activation may also be triggered during attacks of microangiopathy in TTP. Therefore, we investigated the status of the plasminogen activation system in plasma samples from TTP physiological agonists induced complete and irreversible platelet aggregation in n t th the e e pr r res e esen en ence ce ce o of treptokinase-activated plasminogen ( Figure 4A,B) . However, we found that the initial phase of pl lat at tel el elet et et a agg gg ggre re ega ati ti io on on was delayed, suggesting an a a aux ux xiliary role for r VW VWF F F d d during the initiation of ag ggr greg e ate form mat at tio o on. n U U Und nd nder er er f f flo lo ow, w, p p pla la l t te ele et ag g gg gr rega a ate e e fo o orm rm mat at tio o on n o on i imm mm mob b bil iliz iz zed e ed c col ol o la la lage ge en at a at ar rte te teri ri ial al al s she he ear ar ar r rem em ma ai aine ned d u un unaf affe fe fect ct cted ed ed i i in n n th th he e e pr pr pre e esen en ence ce e o o of f s st stre e ept pt ptok ok okin in ina as se-e--ac ac a ti ti iva a ate ted d d pl pl plas asmi mi mino nog ge gen n n 98.2-107.5) ) ); ; n= n= n 19 19 9) ) ) ( ( (Fi Fi F gu gu g re re re 5 5 5B B B). ). ) H H How ow owev ev ever er er, , no no no e evi vi vide de enc nce e e fo fo for r r 2-2-2 an a a ti ti tipl pl plas as asmi mi min n n de de efi fi fici ci cien en ency cy c was (0.93-1.57); n=19). Since thrombocytopenia serves as a cardinal sign for microangiopathy, we categorized all our patient samples by platelet counts and further investigated the association with PAP-complex levels. We found that these complexes were predominantly elevated (3.89 g/mL (1.65-5.99)) in patients with platelet counts below 50x10 3 platelets/ L (n=11), representing severe microangiopathy ( Figure 5D ; acute TTP samples in closed circles; remission samples in open circles). In the second category (50-100 x10 3 platelets/ L; n=8), PAPcomplexes were only modestly increased (1.80 g/mL (1.30-2.00)) over the third and higher categories (>100 x10 3 / L), which had normal PAP-complex levels (1.08 g/mL (0.98-1.47); n=28). This indicates that plasminogen activation mainly occurs in patients during severe thrombotic microangiopathy.
We next investigated the relationship between ADAMTS13 activity and plasminogen activation in further detail. In TTP patients with undetectable ADAMTS13 activity, PAPcomplexes were elevated, whereas they were normal in samples with low (1-20%) and moderateto normal activity (20-100%) (Supplemental Figure 5A) . However, this negative association between ADAMTS13 activity and PAP-complex levels only held true in acute TTP patients (Supplemental Figure 5B ), but was absent in patients in remission (Supplemental Figure 5C ).
This suggests that the state of TTP disease activity (i.e. microangiopathy), rather than the absence of ADAMTS13 activity, induces plasminogen activation in TTP patients. We further explored this rationale over time in repeated samples from three individual acute TTP patients that were taken on admission (indicated by day 0) and on several days during plasmapheresis treatment (sampled prior to plasmapheresis). In our first patient, platelet counts were directly related to ADAMTS13 activity: with increasing ADAMTS13 activity, platelet counts were correspondingly higher ( Figure 5E (patient A) ; open symbols; days after admission are shown hrombotic microangiopathy.
We next investigated the relationship between ADAMTS13 activity and plasminogen ac cti ti iva va vati ti tion on n i i in n n f furt rt the he her r detail. In TTP patients with h u u un nd detectable AD DAM AM A TS TS TS1 13 activity, PAPco om mp mplexes we ere re el l leva va ate ted, d d, w whe he here reas as s t t the hey y w wer re e n norm m ma al in n n sa samp mp mple les s wi w with th l l low ow w ( ( ). H How ow owe ev ever er er, , th th his s s n neg eg egat at ativ ive e e a a asso o oci i iat atio io on n between AD DAM AM AMTS TS TS13 13 1 a a act c iv iv vit it ty y y an an and d d PA PA P P-P-P-co co comp mp mple le ex x x le le eve ve v ls s o o onl nl nly y y he he held ld ld t tru ru rue e e in in in a a acu cu c te e e T T TTP TP TP p p patients above the symbols). Inversely, PAP-complex levels were high in this patient when platelet counts were low and normalized with higher platelet counts ( Figure 5E ; closed symbols). In two other patients, platelet counts corrected while ADAMTS13 activity remained undetectable ( Figure 5E (patient B) and Supplemental Figure 5D (patient C) ). However, in good correspondence to our first patient, PAP-complexes in these patients were elevated during severe thrombocytopenia, but normalized with increasing platelet counts. These data indicate that plasmapheresis does not always restore ADAMTS13 activity and that thrombotic microangiopathy triggers plasminogen activation in human patients.
Thrombolytic therapy attenuates symptoms of acute thrombotic thrombocytopenic purpura in Adamts13 -/-mice
We earlier found that exogenous plasminogen activators, such as streptokinase, can be used to degrade platelet-VWF complexes on endothelial cells and in suspension when ADAMTS13 is absent. We therefore continued to investigate whether thrombolytic agents have therapeutic value in vivo in a mouse model for acute thrombotic thrombocytopenic purpura. Intravenous administration of a high dose of rhVWF into Adamts13 -/-mice leads to the formation of TTP-like symptoms, with thrombocytopenia as a cardinal sign. 15 In continuation of our earlier experiments, we chose to investigate the therapeutic potential of streptokinase, which specifically reacts with human plasminogen. 16 Hereto, we challenged mice by administration of rhVWF, while simultaneously administering human plasminogen. Twenty-four hours after this challenge, platelet counts in these mice were reduced to 140. We earlier found that exogenous plasminogen activators, such as streptokinase, can be used to de egr gr grad ad ade e e pl pl plat at atel e e et t-V -V -VW WF complexes on endothelia al l l c ce el lls and in susp p pen e e si ion on on w when ADAMTS13 is b ab bse e ent n . We the ere re efo o ore e c c con n nti ti tinu nu nued ed ed t to o o in in nve ve est t tigat t te whe e eth h her th th hro romb mb mbol oly yt ytic ic a ag gen n nts s ha ha have ve t t the he hera ra r p p peut ut utic ic hours after rhVWF challenge. However, several thrombi were dispersedly found in various tissues of challenged mice, but no thrombi were seen anywhere in mice that had received thrombolytic treatment ( Figure 6C shows liver sections). Together, these experiments indicate that the induction of plasminogen activation in vivo attenuates thrombotic microangiopathy.
Discussion
Attacks of TTP are hallmarked by occlusion of the microvasculature by platelet-VWF complexes and are life-threatening unless treated. ADAMTS13 deficiency forms an important risk factor for TTP attacks. 24 Intriguingly, both patients and knockout mice with continuous deficiency do not present with continuous symptoms of TTP, suggesting that additional susceptibility factors beyond ADAMTS13 deficiency modify the development of TTP attacks. 25 In the present studies, we explored the hypothesis that a second enzyme can substitute for ADAMTS13 in its absence.
Several candidate enzymes have been identified in vitro, such as thrombin, neutrophil elastase, granzyme B and plasmin. 8 Here, we chose to investigate the potential involvement of plasmin in hours after rhVWF challenge. However, several thrombi were dispersedly found d i in n va vari ri riou ou ous s s issues of challenged mice, but no thrombi were seen anywhere in mice that had received h hro ro omb mb mb l ol olyt yt ytic ic ic tre eat at atm m ment ( Figure 6C shows liver s s sec ec e t tions). Togeth her e e , th h hes es ese e experiments indicate h h hat t t t the inducti tion on n o of f p p pla lasm sm smin in inog og ogen en a ac ct ctiv v va at tion n n f f in n n viv v vo o att t ten en nua ua ate e es s th th hro o omb mb bo ot o i ic c m m mic ic cro roan an angi gi giop op pat at thy h hy.
by guest on April 13, 2017 http://circ.ahajournals.org/ Downloaded from TTP. Our in vitro experiments show that platelet-VWF complexes can be efficiently degraded through uPA-dependent plasminogen activation on endothelial cells (Figure 1) . This can take place through direct lysine-dependent binding of plasminogen to VWF (Figure 2) . Furthermore, exogenously added thrombolytic agents degrade platelet-VWF complexes with equal efficacy and can be securely controlled by the administration of lysine-analogues (Figure 3) . In contrast, plasminogen activation has little effect on primary hemostasis in vitro (Figure 4) . These findings indicate that platelet-VWF complexes, rather than platelet aggregates in general are susceptible to degradation by plasmin. The gradual cleavage of globular VWF by plasmin has been previously reported. 7, 8 We here propose that the efficiency of VWF cleavage by plasmin is a function of its conformation: plasmin has limited affinity for the binding to-and cleavage of globular VWF, but unfolding of VWF strongly enhances this process. As a result, uPA-triggered plasminogen activation destroyed platelet-VWF complexes on endothelial cells and in suspension in a matter of seconds, which could be recapitulated by streptokinase-activated plasminogen. Based on these in vitro findings, we propose a working model for the activation of plasminogen in response to obstructive platelet-VWF complexes (Figure 7) . In the complete absence of ADAMTS13, platelets, as well as ultralarge VWF multimers are present in the circulation. Obstructive microthrombi do not spontaneously form until an elusive triggering event occurs. At this moment, vascular endothelial cells are the first to register differences in oxygenation and respond to hypoxia through expression of extracellular uPAR. 13 In a final step, plasminogen is activated on the activated endothelial cell surface with the aim to remove the obstructions.
In the past, there has been enigmatic evidence for plasminogen activation in acute TTP patients. 21, 26 In our studies, we found elevated PAP-complexes, representing plasminogen function of its conformation: plasmin has limited affinity for the binding to-and d c c cle le eav avag ag age e e of of of globular VWF, but unfolding of VWF strongly enhances this process. As a result, uPA-triggered pl las as smi mi min no noge ge gen n acti ti iva va vati t on destroyed platelet-VWF F c c com mplexes on en ndo d d th hel el eli ia ial cells and in u usp p pen e sion in a a ma ma matt ter er r o o of f f se se seco co con nd nds, s, w w wh hi ich h h co ou ul ld be e e r r recap ap apit itul ul lat at ted ed b by y y st stre re ept tok ok kin in inas ase-e-ac ac a ti ti tiva vate e ed d d pl plas as asmi mi mino no n ge ge gen. n. n B Ba a ase ed ed o on n th th t e ese e e in n n v v vit it itro r ro f fi find nd ndin in ings gs g , , we we we p p pro ro opo po pose se se a a w w wor or rki ki ing ng ng m m mo od odel el l f f for or o t the he he act ct tiv v vat atio io on n of o plasminogen n in in in r res es espo po pons ns n e e e to o o o o obs bs b tr tr truc uc u ti ti tive ve e p p pla la late te tele le let-t-t VW VW VWF F F co co omp mp mple le lexe xe xes s s (Fi Fi Figu gu gure re re 7 7 7). ). ) I I In n n th th the e e co co c mplete activation, in a group of TTP patients with acute microangiopathy (Figure 5 ). However, in TTP patients in remission (i.e. without microangiopathy) no plasmin was generated. This is in good correspondence to our proposed model (Figure 7) : microvascular obstructions cause hypoxia, resulting in plasminogen activation on endothelial cells. It is seemingly paradoxal that plasminogen activation takes place, especially in those patients that suffer from disease.
Apparently, in these patients, plasmin activity is insufficiently capable of fully preventing clinical problems. However, it is most likely that an avalanche-like sequence of intravascular events precedes the moment of clinical presentation in the hospital: in a first phase, continuously forming platelet agglutinates begin obstructing the microvasculature. In further stages, these obstructions grow in size and accumulate more platelets until clinical symptoms appear. In the situation where plasmin is able to clear obstructed vessels at an early stage, a TTP patient would not present him/herself to the hospital and would not be included in our patient group. In other words, patients that experienced an attack of microangiopathy that was successfully countered by endogenous plasminogen activation were by definition not included in our study. However, we
propose that even in our group of acute TTP patients, the observed plasminogen activation is not without purpose; it may help to slow down disease progression. Indeed, it is presently difficult to estimate what would happen when a TTP patient would not have the capacity to recruit plasmin at sites of microvascular occlusion. Mice that are deficient in ADAMTS13 do not spontaneously develop TTP-like symptoms, unless challenged with shigatoxin 25 or supraphysiological amounts of rhVWF. 15 It remains currently unknown what factors beyond ADAMTS13 deficiency modify the susceptibility of mice to develop TTP, but certain strains are more susceptible than others.
25
Targeting factors of the plasminogen activation system in mouse models for TTP may help to provide new insights.
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In our group of 32 acute TTP patients, we found no evidence that ADAMTS13 deficiency was related to 2-antiplasmin deficiency, in contrast to a recently published case report. 21 How to reconcile these apparently contradicting findings? In the case report, the cause for the (transient) 2-antiplasmin deficiency remained uncertain. However, 2-antiplasmin deficiency can either be caused by genetic abnormalities, or become depleted through consumption. This is possible since plasminogen is more abundantly present in the circulation (2.4 M) than its inhibitor 2-antiplasmin (1 M). Subsequently, the continuous formation of plasmin would result in the continuous formation of PAP-complex until the inhibitor runs out. We hypothesize that this was the case in the 2-antiplasmin deficient TTP patient. 21 We propose the following sequence of events: 1) The patient had a pre-existing ADAMTS13 deficiency; 2) After a trigger, the patient developed an episode of microangiopathy (when the remaining ADAMTS13 was insufficiently protective); 3) Plasminogen activation was triggered to degrade VWF in microvascular obstructions until all 2-antiplasmin was consumed. Finally, the remaining uncontrolled plasmin slowly degraded the remaining ADAMTS13 (as collateral damage).
In a final set of experiments, we show that thrombolytic therapy is therapeutic in a mouse model for acute thrombotic thrombocytopenic purpura (Figure 6 ). Administration of thrombolytic therapy resolved thrombocytopenia and platelet complexes were no longer detectable in the circulation, or found in the microvasculature. Although this therapeutic opportunity needs to be further explored, it is an attractive idea that conventional and commonly available therapeutic agents may be valuable in the treatment of TTP attacks. Intuitively, it appears dangerous to administer thrombolytic drugs (with bleeding as a well-known side effect) to thrombocytopenic patients. However, our experiments suggest that thrombolysis may actually be helpful in restoring primary hemostasis by restoring platelet counts (Figure 6A ), while equence of events: 1) The patient had a pre-existing ADAMTS13 deficiency; 2) 2) A A Aft ft f e er r a a a t t tri ri rigg gg g er e , , he patient developed an episode of microangiopathy (when the remaining ADAMTS13 was n nsu su uff ff ffic ic ici ie ient nt ntly ly ly pro ro ote te tect c ive); 3) Plasminogen activat at atio ion n was triggere ed d d to d d deg eg egra r de VWF in m mic cr crovascular r ob ob obs st tru uct c ctio o ons ns ns u u unt nt ntil il a a all ll l 2 2 2-a a antip p pla a asmi i in n wa a as s co con ns nsum umed ed d. Fi Fi in n nal lly, y, t th he he r rem em emai ai aini n n ng ng ng un unco co c nt nt ntro roll lled ed ed p pla lasm sm smin in s slo o owl w y y de degr gr grad ad aded ed t the he he r r re e ema ma main in nin n ng g g AD AD ADAM AM AMTS TS T 13 13 ( ( (as as a co ol olla la ate te t ra ra ral l da da dam ma mag ge ge). ). )
In a f fin in nal al al s s set et et o of f f ex e e pe pe peri ri rime me ent nt n s, s, , w we e e sh sh show ow ow t tha ha hat t th th thro ro r mb mb mbol ol o yt yt y ic ic ic t t the he era ra rapy py py i i is s s th th ther er rap ap apeu eu euti ti tic c c in a mouse e e removing harmful obstructions from the vasculature at the same time. Additionally, the dosing of thrombolysis required to degrade a platelet-VWF complex is expectedly lower than the dose required to degrade a fibrin-rich thrombus: in our experiments, we applied a single dose of streptokinase that approximately represented 20% of the loading dose (in concentration)
commonly given to resolve pulmonary embolism and stroke in human patients. Finally, should the desired effects of thrombolysis in TTP patients be achieved, it is expectedly possible to limit further plasmin activity through administration of lysine analogs, such as ACA ( Figure 3E ).
The majority of TTP patients have ADAMTS13 deficiency as a result of inhibitory antibodies against this metalloprotease. Currently, high volumes of plasma exchange are required to overcome these antibodies. It is attractive to consider the use of thrombolytic therapy to effectively bypass anti-ADAMTS13 antibodies.
In conclusion, we propose that endogenous plasminogen activation as is seen during TTP-related microangiopathy is meant for local clearance of microvascular obstructions. This last line of proteolyic defense can operate independently of other enzymes. Based on our findings, we propose that the plasminogen activation system forms a modulating factor in the events that cause microangiopathy, which may help to explain the episodal nature of TTP. Future studies will need to identify the reasons for which the plasminogen activation system falls short to completely prevent microangiopathy in patients that present with episodes of acute TTP.
However, stimulation of plasminogen activation with readily available conventional thrombolytic agents may have therapeutic value by stimulating the breakdown of vascular obstructions in thrombotic microangiopathy.
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